1432908-05-8
1432908-05-8 結(jié)構(gòu)式
基本信息
PAK小分子抑制劑(FRAX1036)
FRAX1036
FRAX-1036
FRAX 1036
FRAX1036 (Free base)
Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-[2-chloro-4-(6-methyl-2-pyrazinyl)phenyl]-8-ethyl-2-[[2-(1-methyl-4-piperidinyl)ethyl]amino]-
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-19538 | FRAX1036 FRAX1036 | 1432908-05-8 | 1mg | 600元 |
| 2026/06/05 | HY-19538 | FRAX1036 FRAX1036 | 1432908-05-8 | 5mg | 1100元 |
| 2026/06/05 | HY-19538 | FRAX1036 FRAX1036 | 1432908-05-8 | 10mM * 1mLin DMSO | 1254元 |
常見問題列表
|
PAK1 23.3 nM (Ki) |
PAK2 72.4 nM (Ki) |
PAK4 2.4 μM (Ki) |
FRAX1036 is a PAK inhibitor with K i s of 23.3 nM, 72.4 nM, and 2.4 μM for PAK1, PAK2 and PAK4, respectively. FRAX1036 (2.5 μM) incombination with docetaxel alters stathmin phosphorylation, induces the apoptotic marker cleaved PARP and increases kinetics of apoptosis in MDA-MB-175 and HCC2911 cells; also alters microtubule organization, mitosis and cell fate in U2OS cells. Moreover, FRAX1036 shows significantly effective inhibition on U2OS cells. FRAX1036 (10 μM) affects the proliferation of non-small cell lung cancer (NSCLC) cells when added to KRAS prenylation inhibitors.